Intravenous prostaglandin E1 (alprostadil) bolus in ductus arteriosus-dependent CHD: valid or absolutely...

Area of Science:

• Pediatric Cardiology
• Neonatal Critical Care
• Pharmacology

Background:

• Prostaglandin E1 (alprostadil) is used for ductus arteriosus-dependent congenital heart disease (CHD) and pulmonary hypertension.
• Intravenous infusion protocols for alprostadil are established, involving loading and maintenance doses with a delayed onset of action.

Purpose of the Study:

• To report the efficacy of a bolus administration of alprostadil in patients with pulmonary atresia experiencing ductal spasm during cardiac catheterization.
• To assess the immediate impact of alprostadil bolus on pulmonary blood flow and patient stability.

Main Methods:

• Case series of three patients with pulmonary atresia presenting with hypercyanotic spells due to ductal spasm during cardiac catheterization.
• Administration of a bolus dose of alprostadil to reverse ductal spasm.
• Subsequent successful stent placement in the pulmonary artery.

Main Results:

• Alprostadil bolus administration immediately reversed ductal spasm in all three patients.
• Pulmonary blood flow increased, leading to immediate stabilization of the patients' condition.
• Successful stent placement was achieved without serious complications or sequelae post-bolus administration.

Conclusions:

• A bolus of alprostadil can be an effective emergency treatment for ductal spasm in patients with pulmonary atresia during cardiac catheterization.
• Further studies are warranted to establish alprostadil bolus as a recommended intervention for life-threatening ductal spasms.